Genextra
Genextra is a privately owned holding company based in Italy, focused on investing in early-stage life science companies. Its mission is to identify innovative research in life science and to advance novel therapies and tools by creating successful business initiatives. With no territory limit, it benefits from access to top Italian science and supports inventors with capital, strategic, operational, and financial guidance. The company aims to back inventors and identify exceptional investment opportunities to shepherd them to maturity.
Industries
Nr. of Employees
small (1-50)
Genextra
Products
Transcatheter mitral valve replacement (portfolio investment)
Development of a transcatheter mitral valve replacement device for treatment of mitral valve disease.
Targeted immunotherapy for solid tumors (portfolio investment)
Development of targeted immunotherapy approaches aimed at treating solid tumor cancers.
Nanotechnology-based liquid biopsy platform (portfolio investment)
Development of a liquid biopsy platform leveraging nanotechnology for detection and analysis of circulating biomarkers.
Erythrocyte-mediated therapies for rare diseases (portfolio investment)
Development of therapeutic approaches using erythrocytes as carriers for sustained delivery of therapeutics to treat rare diseases.
Transcatheter mitral valve replacement (portfolio investment)
Development of a transcatheter mitral valve replacement device for treatment of mitral valve disease.
Targeted immunotherapy for solid tumors (portfolio investment)
Development of targeted immunotherapy approaches aimed at treating solid tumor cancers.
Nanotechnology-based liquid biopsy platform (portfolio investment)
Development of a liquid biopsy platform leveraging nanotechnology for detection and analysis of circulating biomarkers.
Erythrocyte-mediated therapies for rare diseases (portfolio investment)
Development of therapeutic approaches using erythrocytes as carriers for sustained delivery of therapeutics to treat rare diseases.
Services
Equity investment combined with strategic, operational and financial advisory to help companies grow and commercialize technologies.
Equity investment combined with strategic, operational and financial advisory to help companies grow and commercialize technologies.
Expertise Areas
- Life sciences venture investment
- Portfolio company development and acceleration
- Biotech and medtech commercialization support
- Capital markets and fundraising support
Key Technologies
- Transcatheter cardiovascular device development
- Targeted cancer immunotherapy
- Nanotechnology-based liquid biopsy platforms
- Erythrocyte-mediated drug delivery and therapeutics
News & Updates
Intercept Pharmaceuticals, Inc. announced that management will be presenting at an upcoming investor conference.
Intercept Pharmaceuticals, Inc. announced that multiple obeticholic acid (OCA) abstracts will be presented at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Intercept Pharmaceuticals, Inc. announced that management will be presenting at an upcoming investor conference.
Intercept Pharmaceuticals, Inc. announced that multiple obeticholic acid (OCA) abstracts will be presented at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).